(ETON) Eton Pharmaceuticals - Ratings and Ratios

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company specializing in the development, acquisition, and commercialization of treatments for rare diseases. Its product portfolio includes ALKINDI SPRINKLE, the first and only FDA-approved sprinkle formulation for hydrocortisone, designed for pediatric adrenocortical insufficiency; Carglumic Acid, an orphan drug for N-acetylglutamate synthase deficiency; Betaine Anhydrous, addressing homocystinuria; and Nitisinone, a life-long treatment for hereditary tyrosinemia type 1. The company also markets Zeneo, a hydrocortisone autoinjector for acute adrenal crisis. Since its inception in 2017, Eton has focused on improving patient access to critical therapies through its targeted pipeline and commercial strategy.

From a stock perspective, ETON is trading at $15.70 with a 20-day average volume of 286,603 shares. The stock has shown upward momentum, with a 20-day SMA of 16.27 and a 50-day SMA of 14.89, reflecting recent strength. The 200-day SMA of 8.20 highlights significant growth over the past year. With an ATR of 1.08, volatility remains moderate. Fundamentally, ETON has a market cap of $236.92M, a forward P/E of 17.92, and a P/S ratio of 10.90, indicating a rich valuation. The negative RoE of -34.30% reflects current losses but may improve as revenues scale.